Shares of Aclaris Therapeutics (NASDAQ:ACRS) soared 60% Tuesday, the day after the company announced it was licensing two ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...

Energy and Infrastructure Transition Analyst Lewis holds a virtual meeting with management on November 22 hosted by BTIG. Don't Miss out on Research Tools: Discover the latest stocks recommended by ...

BTIG Research has recently initiated Douglas Elliman Inc (DOUG) stock to Neutral rating, as announced on July 18, 2023, according to Finviz. Analyst ratings are significant because they provide ...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that its Digital Health Forum will take place on Monday, November 25, 2024. The event will be hosted by David Larsen, CFA, BTIG Healthcare IT and ...

BTIG analyst Gregory Lewis maintained a Buy rating on Bloom Energy (BE – Research Report) on November 15 and set a price target of ...

Jonathan Krinsky, BTIG chief market technician, joins CNBC's Closing Bell to discuss market outlooks.

BTIG Research began coverage on shares of VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a ...

It has been nearly three years — and four CEOs — since the union labor movement rocked the business and a Starbucks in ...

Plug Power (NASDAQ:PLUG) -1.1% in Thursday's trading as BTIG Research downgrades shares to Neutral from Buy, saying the company is "turning the corner but still [has] a lot of work to do." ...

CEO of Simulations Plus, Shawn O’Connor, will participate in a panel discussion at the virtual BTIG Digital Health Forum on ...